Next-Generation Prostate Cancer Biomarker Shows Promise

Cleveland Clinic urologists are playing leading roles in the development of next-generation prostate cancer biomarkers. One new test under investigation, prostate specific antigen/solvent interaction analysis (PSA/SIA), shows promise in improving the diagnostic accuracy of screening and early detection strategies by differentiating PSA structural changes induced by cancer from those of benign glands.

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy